Skip to main content
Basilea Pharmaceutica AG logo

Basilea Pharmaceutica AG — Investor Relations & Filings

Ticker · BSLN ISIN · CH0011432447 LEI · 391200TTZP8EIPSJ5J20 SW Manufacturing
Open in API
Filings indexed 55 across all filing types
Latest filing 2023-10-02 Regulatory Filings
Country CH Switzerland
Listing SW BSLN

About Basilea Pharmaceutica AG

https://www.basilea.com/

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company that develops and commercializes innovative pharmaceutical products. The company focuses on meeting the medical needs of patients with severe and life-threatening conditions, particularly bacterial and fungal infections. Its core activities revolve around its key anti-infective products, Cresemba and Zevtera, with a strategy to establish them as global brands. Basilea has a proven track record of advancing drugs from research and development through to market commercialization, aiming to become a leading company in the anti-infectives field.

Recent filings

Filing Released Lang Actions
Basilea gibt bekannt, dass die FDA den Zulassungsantrag für das Antibiotikum Ceftobiprol zur Prüfung angenommen hat
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is dated October 2, 2023. It announces that the FDA has accepted the New Drug Application (NDA) for the antibiotic Ceftobiprole and set a PDUFA target date of April 3, 2024. This is a material, non-public event disclosure typical of regulatory requirements for listed companies, specifically concerning regulatory progress (FDA acceptance of a drug application). Since it is an announcement about a regulatory event (drug application acceptance) rather than a full financial report (10-K, IR) or a general regulatory filing fallback (RNS), it fits best under the category for general corporate news that is not covered by other specific codes. Given the options, this type of material corporate update, especially concerning regulatory milestones in the pharmaceutical sector, is often classified as a general Regulatory Filing (RNS) if a more specific category like 'Legal Proceedings Report' (LTR) or 'Capital/Financing Update' (CAP) does not apply. However, since it is a formal, time-sensitive announcement of a significant corporate event (FDA acceptance), and it is not a financial report, a dividend notice, or a management change, the most appropriate general regulatory/corporate disclosure category is RNS, as it is a mandatory disclosure outside the standard financial reporting cycle.
2023-10-02 German
Basilea reports strong revenue and profit growth in first half-year 2023
Earnings Release Classification · 1% confidence The document is explicitly titled as an 'Ad hoc announcement pursuant to Art. 53 LR' and details the financial results for the 'first half-year ended June 30, 2023'. It provides key financial highlights, a summary table of H1 2023 vs H1 2022 results, updated full-year guidance, and information about an upcoming conference call. This structure—a comprehensive report on a period shorter than a year (six months)—is the definition of an Interim/Quarterly Report. Although it contains elements of an Earnings Release (ER) via the bulleted highlights, the depth of the financial summary and tables confirms it is the full Interim Report, not just the initial release. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-15 English
Basilea meldet starkes Umsatz- und Gewinnwachstum im ersten Halbjahr 2023
Earnings Release Classification · 1% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and details the financial results for the first half of the fiscal year 2023 (H1 2023). It presents key financial highlights, a summary of results, updated guidance for the full year 2023, and announces a conference call to discuss these results. This structure—a comprehensive release of period-specific financial performance data that is not the full annual report (10-K)—is characteristic of an Interim/Quarterly Report (IR). Although it contains elements of an Earnings Release (ER) by providing highlights, the depth of the financial tables and management discussion points towards the more comprehensive Interim Report category (IR). It is not merely an announcement of a report (RPA) because it contains the full substance of the results, not just a link to an attached document. H1 2023
2023-08-15 German
Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole
Regulatory Filings Classification · 1% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' dated August 04, 2023. It details that Basilea Pharmaceutica Ltd has submitted a New Drug Application (NDA) to the FDA for its antibiotic ceftobiprole. The text focuses on the submission, clinical trial data, regulatory status (Priority Review, QIDP designation), and expected decision timeline. This is a specific corporate action announcement related to regulatory progress for a product, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is an announcement about a significant corporate event (NDA submission) that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory regulatory disclosure (Ad hoc announcement) that doesn't match the other specific types like DIRS, DIV, or DEF 14A. Given the context of a pharmaceutical company announcing a major regulatory filing milestone, RNS is the most appropriate general regulatory disclosure category.
2023-08-04 English
Basilea gibt Einreichung eines Zulassungsantrags bei der US-amerikanischen Arzneimittelbehörde Food and Drug Administration für Antibiotikum Ceftobiprol bekannt
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and is dated August 4, 2023. It announces a significant corporate event: the filing of a New Drug Application (NDA) with the FDA for the antibiotic Ceftobiprol. This type of material, which communicates material, non-public information to the market immediately, is characteristic of a regulatory disclosure. Since it is an announcement of a specific corporate action (filing a major regulatory application) rather than a full financial report (10-K, IR), a management discussion (MDA), or a transcript (CT), it fits best under the general category for regulatory announcements that are not otherwise specified. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-standard, time-sensitive corporate disclosure that isn't a standard financial report or management update. It is not a Report Publication Announcement (RPA) because it is announcing the *filing* of an application, not the publication of a previously prepared report like an annual report or earnings release.
2023-08-04 German
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea
Regulatory Filings Classification · 1% confidence The document is titled "Ad hoc announcement pursuant to Art. 53 LR" and reports on triggering milestone payments based on sales performance of a licensed drug (Cresemba). It details financial events (milestone payments totaling USD 26.25 million) and provides business updates, but it is not a comprehensive annual report (10-K), a quarterly report (IR), or a formal earnings release (ER) which typically includes full period financial statements. It is a specific, material corporate event announcement. Since it announces a significant financial/business development that doesn't fit the specific categories like DIV, CAP, or MANG, and it is not a transcript (CT) or a presentation (IP), the most appropriate general category for a material, non-standard regulatory announcement is Regulatory Filings (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to another document.
2023-06-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.